Case Study: Innovative Life Sciences Manufacturer achieves scalable, unified market access for rare disease therapies with IntegriChain’s ICyte Platform

Achieving Operational Success for Rare Disease Therapy Using a Unified Platform

Innovative Life Sciences Manufacturer, a rapidly growing company developing therapies for rare diseases using decentralized “research pods,” needed a scalable Market Access infrastructure to aggregate patient, channel, contract and pricing data and roll it up to the parent company. Facing siloed data, manual Excel models, and the need for auditability and timely insights, the customer engaged IntegriChain and its ICyte Platform (Patient Access and GTN solutions) to standardize processes and centralize data.

IntegriChain deployed the ICyte Platform (Analytics, Portal, Data Mart, Data Refinery) to unify channel and patient data, tokenize/de‑identify patients, and deliver near‑real‑time KPIs (Time‑to‑Fill, Fill Rate, Time on Therapy, Proportion of Days Covered) plus GTN scenario modeling. The solution eliminated manual roll‑ups, freed high‑value resources, improved data accuracy and productivity, and enabled faster, auditable decision‑making across subsidiaries—demonstrating IntegriChain’s ability to scale Market Access for rare disease therapies.